Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$164.66 - $218.08 $71.6 Million - $94.9 Million
-434,988 Reduced 75.7%
139,618 $23.6 Million
Q2 2023

Aug 14, 2023

BUY
$176.32 - $240.22 $14.7 Million - $20 Million
83,464 Added 16.99%
574,606 $125 Million
Q1 2023

May 12, 2023

SELL
$161.33 - $204.36 $9.22 Million - $11.7 Million
-57,179 Reduced 10.43%
491,142 $89.2 Million
Q4 2022

Feb 10, 2023

SELL
$191.53 - $236.82 $28.1 Million - $34.7 Million
-146,457 Reduced 21.08%
548,321 $108 Million
Q3 2022

Nov 14, 2022

BUY
$123.79 - $277.42 $51.1 Million - $114 Million
412,548 Added 146.17%
694,778 $156 Million
Q2 2022

Aug 12, 2022

SELL
$93.97 - $143.33 $8.2 Million - $12.5 Million
-87,315 Reduced 23.63%
282,230 $35.7 Million
Q1 2022

May 13, 2022

BUY
$98.9 - $132.37 $12.6 Million - $16.9 Million
127,840 Added 52.89%
369,545 $46.9 Million
Q4 2021

Feb 11, 2022

SELL
$110.64 - $159.4 $7.73 Million - $11.1 Million
-69,911 Reduced 22.43%
241,705 $31.7 Million
Q3 2021

Nov 09, 2021

SELL
$101.2 - $125.87 $5.77 Million - $7.18 Million
-57,030 Reduced 15.47%
311,616 $38.1 Million
Q2 2021

Aug 11, 2021

BUY
$107.45 - $135.95 $5.92 Million - $7.49 Million
55,085 Added 17.57%
368,646 $42 Million
Q1 2021

May 11, 2021

BUY
$95.46 - $133.08 $3.61 Million - $5.03 Million
37,834 Added 13.72%
313,561 $37.7 Million
Q4 2020

Feb 09, 2021

BUY
$75.23 - $109.23 $500,129 - $726,161
6,648 Added 2.47%
275,727 $28 Million
Q3 2020

Nov 12, 2020

BUY
$71.31 - $109.74 $537,320 - $826,890
7,535 Added 2.88%
269,079 $20.8 Million
Q2 2020

Aug 14, 2020

SELL
$62.14 - $117.21 $3.23 Million - $6.1 Million
-52,031 Reduced 16.59%
261,544 $29.2 Million
Q1 2020

May 14, 2020

BUY
$60.41 - $115.92 $7.29 Million - $14 Million
120,612 Added 62.51%
313,575 $22.6 Million
Q4 2019

Feb 14, 2020

BUY
$11.44 - $123.99 $2.21 Million - $23.9 Million
192,963 New
192,963 $14.5 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.